ADOCIA a biotechnology company dedicated to protein delivery

  • Contact Us
  • Linkedin
  • RSS
  • LANGUAGES
    • English English
    • Français Français
  • Presentation
    • About Adocia
    • Founders
    • Management
    • Board of Directors
    • Team
    • Scientific Advisory Board
    • Symbol
  • Technology
    • BIOCHAPERONE®
    • Intellectual property
    • Publications
  • Products
    • Pipeline
    • BIOCHAPERONE® LISPRO
    • BIOCHAPERONE® COMBO
    • M1Pram
    • BIOCHAPERONE® GLUCAGON
    • BIOCHAPERONE® Gla GLP-1
    • BioChaperone® Glucagon GLP-1
    • Cell Therapy
  • Partnering
    • Licensing Opportunities
    • Contact
  • Financials
    • Home Investors
    • Regulated Information
    • Documentation
    • Shareholders
    • Shareholders meeting
    • Governance
    • Investors Contact
  • Careers
    • Working at Adocia
    • HR Policy
    • Spontaneous application
    • Offers
  • News & Events
    • Press Releases
    • Upcoming Events

Partnering

Licensing Opportunities

Adocia is developping four clinical-stage products and one preclinical product.

Insulins

Insulin and insulin analogs are our main focus and area of expertise. Our products are innovative formulations of blockbuster insulins that improve and facilitate patients’ insulin therapy. This portfolio of insulins is an opportunity both for established companies in the diabetes field or for newcomers entering the insulin market.

Licensing opportunities:

  • BioChaperone® Lispro a more physiological short-acting insulin for better outcomes.
  • BioChaperone® Combo which delivers a fast-acting insulin analog and long-acting insulin glargine in a single injection.
  • M1 Pram the first co-formulation of prandial insulin and pramlintide. It would meet the pressing medical need for tight postprandial glycemic control and lower glycemic variability without adding an additional product and more injections.
  • BioChaperone® glucagon: Using the BioChaperone® technology, Adocia aims to develop a stable aqueous solution of recombinant human glucagon, that may be used in varied settings, including the treatment of severe hypoglycaemia and the use in an artificial pancreas.

Partner

Adocia is looking for patient-oriented partners who share our culture in innovation, and may bring complementary expertise in:

  • Medical Science and Medical Practice.
  • Late-stage clinical development.
  • Regulatory Affairs.
  • Marketing and commercialization.

For more information on the collaboration opportunities with Adocia, please contact Adocia’s Business Development.

Partnering

  • Licensing Opportunities
  • Contact

A la Une / Spotlight

  • In January, read Adocia’s article on M1Pram published in the Journal “Diabetes, Obesity and Metabolism”.

    The scientific journal “Diabetes, Obesity...
  • January 11: Adocia Pipeline and Perspective at the occasion of H.C.WAINWRIGHT BIOCONNECT 2021 CONFERENCE

    Gerard Soula Presentation at H.C. Wainwright Bi...

 

  • Home
  • Terms Of Use
  • Privacy Policy
  • Contact
ADOCIA a biotechnology company dedicated to protein delivery

Copyright ADOCIA © 2018

TOP